Blog

April Marks Parkinson’s Disease Awareness Month

World Parkinson’s Day was instituted on April 11th, 1997 to commemorate the birthday of Dr. James Parkinson, the  man who first formally identified the disease nearly 200 years ago and penned the 1817 work—“An  Essay on the Shaking Palsy.” Today, the month of April marks the resurgence from winter, the beginning of allergy season, and […]

Read More >>

Human Stem Cells vs. Plant Stem Cells

With the combined efforts of biologists, geneticists, and clinicians, enormous progress has been made in the field of regenerative medicine and stem cell technology. Stem cells are one of the most promising advancements to come about in recent years, facilitating developments in ways that were inconceivable a few years ago. Novel pathological mechanisms have been […]

Read More >>

International Stem Cell Corporation Completes Dosing Of Second Cohort In Parkinson’s Disease Clinical Trial

Recently, the International Stem Cell Corporation (ISCO) announced that its eighth participant, which completes the dosing of the second cohort of the clinical trial for Parkinson’s disease, was successfully transplanted with ISC-hpNSC® cells at the Royal Melbourne Hospital in Melbourne, Australia. ISCO’s Executive Vice President and Chief Scientific Officer Russell Kern, PhD, commented, “We are […]

Read More >>

Dr. Russell Kern Interviewed for Neuro-Central Feature

Recently, Neuro Central’s Lauren Pulling had the opportunity to interview Russell Kern, PhD, Executive Vice President and Chief Scientific Officer of the International Stem Cell Corporation (ISCO) that is currently conducting the world’s first-in-human clinical study of neural stem cells in Parkinson’s disease patients and enrolling patients in Melbourne, Australia at the Royal Melbourne Hospital, with […]

Read More >>

Update: ISCO Clinical Trial Patient Kevin Weeks

At 63, real estate icon Kevin Weeks was the picture of good health. He exercised regularly, ate healthy, and didn’t smoke. But, following a week-long cycling tour through the French and Swiss Alps, he returned to his native Australia to attend a friend’s birthday and was greeted by a tidal wave of symptoms synonymous with […]

Read More >>

International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson’s Disease Clinical Trial

CARLSBAD, CA – International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the positive six months interim results of the first cohort of Parkinson’s disease (PD) patients receiving 30 million ISC-hpNSC cells in the ongoing clinical study. All patients in the first cohort […]

Read More >>

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation’s Phase I Clinical Trial for the Treatment of Parkinson’s Disease

IRVINE, Calif., May 23, 2016 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation’s (OTCQB: ISCO) (“ISCO”) for its Phase I clinical trial in Australia for the treatment of moderate to severe […]

Read More >>

International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results

CARLSBAD, CA — March 31, 2016 – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2015. “2015 was a […]

Read More >>